ProCE Banner Activity

NAPOLI 3: Phase III Trial of First-line NALIRIFOX vs Nab-Paclitaxel + Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Conference Coverage
Slideset

Released: January 30, 2023

Expiration: January 29, 2024

No longer available for credit.

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Seagen Inc.